Antibacterial oxazolidinones: Emerging structure-toxicity relationships

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 5, 2010, Pages 565-574

  Renslo, Adam R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mitochondrial protein synthesis inhibition; Monoamine oxidase inhibition; Myelosuppression; Oxazolidinone antibiotics; Protein synthesis inhibitors; Toxicity

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); EPEREZOLID; LINEZOLID; OXAZOLIDINONE DERIVATIVE; PLACEBO; RADEZOLID; TOREZOLID;

ANEMIA; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOCARDITIS; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; IC 50; IN VITRO STUDY; LACTIC ACIDOSIS; LEUKOPENIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; PANCYTOPENIA; PERIPHERAL NEUROPATHY; REVIEW; SKIN INFECTION; THROMBOCYTOPENIA; TOXICITY TESTING;

ANIMALS; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; MITOCHONDRIAL PROTEINS; MONOAMINE OXIDASE; OXAZOLIDINONES; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952281288     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.26     Document Type: Review

References (36)

1. Barbachyn MR, Ford CW. Oxazolidinone structure-ractivity relationships leading to linezolid. Angew. Chem. Int. Ed. Engl. 42(18), 2010-2023 (2003).
2. Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious Gram-positive infections. J. Med. Chem. 51(7), 1981-1990 (2008).
3. Leach KL, Swaney SM, Colca JR et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell. 26(3), 393-402 (2007).
4. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc. Natl Acad. Sci. USA 105(36), 13339-13344 (2008).
5. Ippolito JA, Kanyo ZF, Wang D et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51(12), 3353-3356 (2008).
6. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl. 2), ii9-ii16 (2003).
7. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2), ii17-ii25 (2003).
8. Wilcox MH. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2), ii27-ii35 (2003).
9. French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother. 51(Suppl. 2), ii45-ii53 (2003).
10. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27(8), 1189-1197 (2007).
11. Naruganahalli KS, Shirumalla RK, Bansal V, Gupta JB, Das B, Ray A. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats. Eur. J. Pharmacol. 545(2-3), 167-172 (2006).
12. Hutchinson DK. Oxazolidinone antibacterial agents: a critical review. Curr. Top. Med. Chem. 3(9), 1021-1042 (2003).
13. Gravestock MB. Recent developments in the discovery of novel oxazolidinone antibacterials. Curr. Opin. Drug Discov. Devel. 8(4), 469-477 (2005).
14. Renslo AR, Luehr GW, Gordeev MF. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg. Med. Chem. 14(12), 4227-4240 (2006).
15. Vara Prasad JVN. New oxazolidinones. Curr. Opin. Microbiol. 10, 454-460 (2007).
16. Srivastava BK, Soni R, Patel JZ, Jain MR, Patel PR. Oxazolidinone Antibacterials and Our Experience. Anti Infect. Agents Med. Chem. 7, 258-280 (2008).
17. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother. 58(2), 273-280 (2006).
18. Nam JR, Kim MS, Lee CH, Whang DH. Linezolid treatment for osteomyelitis due to staphylococcus epidermidis with reduced vancomycin susceptibility. J. Korean Neurosurg. Soc. 43(6), 307-310 (2008).
19. Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf. 31(9), 753-768 (2008).
20. Skripkin E, McConnell TS, DeVito J et al. R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. Antimicrob. Agents Chemother. 52(10), 3550-3557 (2008).
21. Shaw KJ, Poppe S, Schaadt R et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52(12), 4442-4447 (2008).
22. Surber J, Mehra P, Manos P et al. Efficacy of TR-701 in an Phase 2 randomized, double-blind study in patients with severe complicated skin and skin structure infections (cSSSI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
23. File T, Bagheri F, Bush L et al. A Phase 2 Study comparing two doses of radezolid to linezolid in adults with uncomplicated skin and skin structure infections (uSSSI). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
24. Prokocimer P, Bien P, Munoz KA, Aster R. Hematological Effects of TR-701, linezolid, and placebo administered for 21 days in healthy subjects. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 12-14 September 2008.
25. Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob. Agents Chemother. 52(5), 1653-1662 (2008).
26. Zhou J, Bhattacharjee A, Chen S et al. Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics. Bioorg. Med. Chem. Lett. 18(23), 6175-6178 (2008).
27. Sciotti RJ, Pliushchev M, Wiedeman PE et al. The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class. Bioorg. Med. Chem. Lett. 12(16), 2121-2123 (2002).
28. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50(6), 2042-2049 (2006).
29. Nagiec EE, Wu L, Swaney SM et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob. Agents Chemother. 49(9), 3896-3902 (2005).
30. Renslo AR, Atuegbu A, Herradura P et al. A distal methyl substituent attenuates mitochondrial protein synthesis inhibition in oxazolidinone antibacterials. Bioorg. Med. Chem. Lett. 17(18), 5036-5040 (2007).
31. Cho YL, Chae SE, Baek SY et al. New oxazolidinones with cyclic amidrazone (i): structure-activity relationship of cyclic amidrazone antibiotics. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
32. Lee H, Cha DS, Kang D-H et al. New oxazolidinones with cyclic amidrazone (III): pharmacokinetics and repeated dose toxicity studies of LCB01-0183 and LCB01-0371. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
33. Reck F, Zhou F, Girardot M et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J. Med. Chem. 48(2), 499-506 (2005).
34. Poel TJ, Thomas RC, Adams WJ et al. Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3- fluoro-4- (1-oxotetrahydrothiopyran-4-yl) phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound. J. Med. Chem. 50(24), 5886-5889 (2007).
35. Penzien JB, Huband M, Leach K et al. In vitro and in vivo activity of PF- 00708093 and PF-02341752: new oxazolidinone antibacterials versus recent bacterial clinical isolates. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12-15 September 2009.
36. Choy A, Colbry N, Huber C, Pamment M, Duine JV. Development of a synthesis for a long-term oxazolidinone antibacterial. Org. Process Res. Dev. 12(5), 884-887 (2008)